Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase an equal number of shares. The common shares are priced at $0.795 each, with warrants priced at $0.005 each and an exercise price of $0.84 per share. The combined gross proceeds are expected to be approximately $2.9 million, with the transactions slated to close on or about Aug. 14, 2026, subject to customary conditions.
This capital infusion is a strategic move for Dyadic, which aims to commercialize its proprietary Dapibus and C1 expression systems. These platforms are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins, addressing the growing demand for sustainable and non-animal protein sources across life sciences, food and nutrition, and bio-industrial markets. The net proceeds from the offering, along with existing cash reserves, will be used for working capital and general corporate purposes, providing the company with additional financial flexibility to advance its research and development efforts and scale its operations.
The significance of this financing lies in its potential to accelerate Dyadic's mission to replace traditional animal-based protein production with more efficient and sustainable alternatives. As global demand for protein continues to rise, the need for scalable and environmentally friendly production methods becomes increasingly critical. Dyadic's technology aims to meet this need by offering a platform that can produce proteins at lower cost and with greater flexibility than conventional methods. This funding could enable the company to bring its products closer to market, potentially impacting industries ranging from pharmaceuticals to food additives.
Aegis Capital Corp. is serving as the exclusive placement agent for the offerings. The company's ability to secure this investment reflects investor confidence in its technology and market potential. For more details on the offering, refer to the full press release at https://ibn.fm/od7FJ.
Dyadic International is a global biotechnology company focused on developing and commercializing scalable, non-animal protein production platforms. Its C1 and Dapibus expression systems are engineered to help customers create more efficient, scalable, and sustainable products. The company's work is aligned with broader industry trends toward sustainability and the reduction of animal-derived materials. More information about Dyadic is available at https://dyadic.com/.
This financing round is a notable step for Dyadic as it seeks to establish its platforms in the market. The additional capital may allow the company to invest in commercialization efforts, partnerships, and further technological advancements. The implications extend beyond the company itself, as successful deployment of its technology could contribute to more sustainable protein production on a global scale. The offering underscores the growing interest in biotech solutions that address environmental and ethical concerns associated with traditional protein sources.
As the transaction closes, stakeholders will be watching how Dyadic utilizes these funds to achieve its strategic objectives. The company's focus on scalable, non-animal protein production positions it well to capitalize on increasing consumer and industry demand for sustainable alternatives. With this capital boost, Dyadic is better equipped to navigate the path toward commercial viability and make a meaningful impact in the biotech and food sectors.
